These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31107252)

  • 1. Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.
    Mansourian M; Ghasemi Ms K; Khorsandi PhD D; Vaseghi G
    Am J Ther; 2020; 27(5):e541-e543. PubMed ID: 31107252
    [No Abstract]   [Full Text] [Related]  

  • 2. Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
    Kretschmer A; Todenhöfer T
    Eur Urol Focus; 2019 Mar; 5(2):114-116. PubMed ID: 30482584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
    Tierney JF; Vale CL; Parelukar WR; Rydzewska L; Halabi S
    Eur Urol Focus; 2019 Mar; 5(2):137-143. PubMed ID: 30713089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina C; Messina M; Boccardo F
    Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
    Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
    Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
    Liu M; Qu S; Liu Y; Yao X; Jiang W
    J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Jilani A; George E; Adler AI
    Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
    ESMO Guidelines Committee
    Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 13. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
    Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
    Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 18. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined androgen blockade in prostate cancer: meta-analyses and associated issues.
    Klotz L
    BJU Int; 2001 Jun; 87(9):806-13. PubMed ID: 11412217
    [No Abstract]   [Full Text] [Related]  

  • 20. New indication sought for bicalutamide.
    Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.